A vaccine being developed by Pfizer has been found to be more than 90 percent effective against Covid-19, the pharmaceutical company said.
The finding was the result of the first independent analysis of any Covid-19 vaccine in phase 3 trials, the final stage before commercial licensing.
The study found that 94 participants who received the two-dose vaccine were protected against the disease 28 days after their first inoculation.
The American firm developed the jab along with Germany’s BioNTech. The efficacy rate is significantly above the 50 percent effectiveness required by the US Food and Drug Administration for a coronavirus vaccine.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.— Pfizer Inc. (@pfizer) November 9, 2020